Flora Adams

Flora Adams is a researcher affiliated with Vrije Universiteit Brussel (VUB) in Brussels, Belgium. Her academic work focuses on cardiovascular medicine and pharmaceutical research, with significant contributions to the field of lipid management and novel therapeutic approaches.

Dr. Adams' research interests center around cardiovascular therapeutics, particularly focusing on bococizumab, LDL cholesterol management, and proprotein convertase 9 inhibition. Her work has contributed to understanding the safety profiles of novel lipid-lowering agents and their efficacy in high-risk patient populations. The fingerprint analysis of her work shows strong emphasis on bococizumab research (100%), safety assessment (29%), LDL cholesterol management (20%), placebo-controlled studies (19%), and proprotein convertase 9 inhibition (16%).

Her most notable publication is the 2017 New England Journal of Medicine article on bococizumab, which has garnered significant attention with 538 citations in Scopus, coverage by 10 news outlets, mentions on 90 X (Twitter) accounts, and references in 5 clinical guideline sources. This research represents important work in the field of cardiovascular risk reduction through novel pharmacological approaches.